Japan will participate in an international clinical trial to identify treatments against infections caused by drug-resistant bacteria, it has been learned.
The Tokyo-based National Center for Global Health and Medicine (NCGM) and Osaka-based drug maker Shionogi & Co. will participate in a trial that will be conducted in 10 countries, starting in spring at the earliest. Shionogi's antibacterial drug will be administered to newborns to test its efficacy.
Japan will join the international initiative to increase treatment options to save the lives of newborns and solve the global problem of drug-resistant bacteria, which are spreading mainly in developing countries.
